Author

B. Beddingfield

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:Arabidopsis· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

C. J. Roy· 2 shared J. Kolls· 2 shared N. Iwanaga· 2 shared X. Qin· 2 shared A. Birnbaum· 1 shared B. Threeton· 1 shared C. Allers· 1 shared C. C. Midkiff· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

C. J. Roy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Acute Respiratory Distress and Cytokine Storm in Aged, SARS-CoV-2 Infected African Green Monkeys, but not in Rhesus Macaques

R. V. Blair, M. Vaccari, L. A. Doyle-Meyers, C. J. Roy, K. Russell-Lodrigue, M. Fahlberg, C. J. Monjure, B. Beddingfield, K. S. Plante, J. A. Plante, S. C. Weaver, X. Qin, C. C. Midkiff, G. Lehmicke, N. Golden, , J. Rappaport

This study compares SARS-CoV-2 infection in aged African green monkeys and rhesus macaques, finding ARDS and cytokine storms in AGMs but not RMs.

bioRxiv · Jun 18, 2020 · PreprintPathology

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix

This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.

bioRxiv · Jun 15, 2020Microbiology

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong, B. Beddingfield, J. Crabtree, R. A. Tripp, X. Qin, J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

bioRxiv · Jun 15, 2020 · PreprintImmunology